Effect of biologics targeting interleukin‐23/‐17 axis on subclinical atherosclerosis: results of a pilot study

• Published in: Clinical and experimental dermatology Vol. 45; no. 5; pp. 560 - 564
• Main Authors: Marovt, M., Marko, P. B., Pirnat, M., Ekart, R.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.07.2020
• Subjects: Arteriosclerosis; Atherosclerosis; Biological products; Cardiovascular diseases; Cytokines; Drug delivery; Monoclonal antibodies; Patients; Psoriasis; Skin diseases; Skin lesions; Vascular diseases
• ISSN: 0307-6938; 1365-2230
• DOI: 10.1111/ced.14180

Summary Background Psoriasis is associated with an increased risk of developing atherosclerotic vascular disease. The hypothesis that treatment of the skin inflammation may decrease the risk of developing atherosclerosis and consequently, cardiovascular disease, is currently a focus of significant attention. Aim To assess the effect of biologic drugs targeting the interleukin (IL)‐23/IL‐17 axis on selected subclinical atherosclerosis parameters in patients with psoriatic disease. Methods In a series of patients with moderate to severe psoriasis who were eligible for biologic therapy, pulse wave velocity (PWV) and intima–media thickness (IMT) were determined before therapy and after 6 months of treatment with biologics (ustekinumab, secukinumab, ixekizumab). Results After 6 months of treatment, a marked clinical improvement of skin lesions was observed in all patients. No significant changes in PWV or IMT values were observed before (8.59 ± 1.96 mm and 0.54 ± 0.9 mm, respectively) and after 6 months (8.89 ± 2.02 mm and 0.53 ± 0.9 mm) of therapy (P = 0.16 and P = 0.74). Conclusions Systemic treatment of patients with a psoriatic disease with biologics targeting the IL‐23/IL‐17 axis has a possibly neutral effect on atherosclerosis. Additional studies are needed to assess the impact of newer biologic treatments on atherosclerosis.